Analyze Diet
Journal of veterinary internal medicine2017; 31(4); 1188-1192; doi: 10.1111/jvim.14718

Blood Glucose and Insulin Concentrations after Octreotide Administration in Horses With Insulin Dysregulation.

Abstract: Octreotide is a somatostatin analog that suppresses insulin secretion. Objective: We hypothesized that octreotide would suppress insulin concentrations in horses and that normal (N) horses and those with insulin dysregulation (ID) would differ significantly in their plasma glucose and insulin responses to administration of octreotide. Methods: Twelve horses, N = 5, ID = 7. Methods: Prospective study. An oral sugar test was performed to assign horses to N and ID groups. Octreotide (1.0 μg/kg IV) was then administered, and blood was collected at 0, 5, 10, 15, 20, 25, 30, 45, 60, 75, and 90 minute, and 2, 3, 4, 6, 8, 12, and 24 hour for measurement of glucose and insulin concentrations. Area under the curve (AUC) values were calculated. Results: Mean AUC values for glucose and insulin did not differ between normal (n = 5) and ID (n = 7) groups after octreotide injection. Significant time (P < .001) effects were detected for glucose and insulin concentrations. A group × time interaction (P = .091) was detected for insulin concentrations after administration of octreotide, but the group (P = .33) effect was not significant. Conclusions: Octreotide suppresses insulin secretion, resulting in hyperglycemia, and then concentrations increase above baseline as glycemic control is restored. Our hypothesis that octreotide causes insulin concentrations to decrease in horses was supported, but differences between N and ID groups did not reach statistical significance when blood glucose and insulin responses were compared. The utility of an octreotide response test remains to be determined.
Publication Date: 2017-05-15 PubMed ID: 28503791PubMed Central: PMC5508354DOI: 10.1111/jvim.14718Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates the impact of the drug Octreotide, a suppressor of insulin secretion, on blood glucose and insulin concentrations in horses, particularly those that have insulin dysregulation. Both normal horses and those with insulin dysregulation were studied, with results indicating notable reductions in insulin levels, though the distinctions between the two groups did not reach statistical significance.

Methodology

  • The study was prospective in nature and involved a total of twelve horses out of which, five were normal and seven had insulin dysregulation.
  • An oral sugar test was conducted initially in order to categorize the horses into two groups: normal (N) and insulin dysregulated (ID).
  • After that, Octreotide of dosage 1.0 μg/kg IV was administered to the horses with blood samples being collected at specific intervals ranging from immediately post administration up to 24 hours later for the measurement of glucose and insulin concentrations in the blood.
  • To quantify the results, the researchers computed the area under the curve (AUC) values for each sample.

Key Findings

  • The mean Area Under Curve (AUC) values for both glucose and insulin did not exhibit any significant variation between the normal (n = 5) and insulin dysregulated (n = 7) groups post-Octreotide injection.
  • The data revealed significant time effects on both glucose and insulin concentrations.
  • While a group x time interaction was identified for insulin concentrations post-Octreotide administration, the group effect itself was found insignificant. The interaction was not significant enough to show a meaningful difference in results between the normal horses and those with insulin dysregulation.
  • Ultimately, the data supported the hypothesis that Octreotide reduces insulin concentrations in horses, causing a temporary hike in blood glucose (hyperglycemia) before rebounding above baseline as glycemic control is reinstated.

Conclusions

  • The study concluded that Octreotide does indeed suppress insulin secretion, leading to a temporary phase of high blood glucose levels (hyperglycemia), before it increases above the baseline as control over glycemic level is regained.
  • However, the differences between horses that were normal (N) and those with insulin dysregulation (ID) did not reach statistical significance when it came to their blood glucose and insulin responses after Octreotide treatment. It implies that the Octreotide impacts the horses in a similar way irrespective of their insulin regulation.
  • The use of an Octreotide response test to determine insulin dysregulation in horses still requires further examination and validation.

Cite This Article

APA
Frank N, Hermida P, Sanchez-Londoño A, Singh R, Gradil CM, Uricchio CK. (2017). Blood Glucose and Insulin Concentrations after Octreotide Administration in Horses With Insulin Dysregulation. J Vet Intern Med, 31(4), 1188-1192. https://doi.org/10.1111/jvim.14718

Publication

ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 31
Issue: 4
Pages: 1188-1192

Researcher Affiliations

Frank, N
  • Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA.
Hermida, P
  • Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA.
Sanchez-Londoño, A
  • Department of Environmental and Population Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA.
Singh, R
  • Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA.
Gradil, C M
  • Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA.
Uricchio, C K
  • Stockbridge School of Agriculture, University of Massachusetts, Amherst, MA.

MeSH Terms

  • Animals
  • Blood Glucose / analysis
  • Female
  • Glucose Tolerance Test / veterinary
  • Horse Diseases / blood
  • Horse Diseases / drug therapy
  • Horses / blood
  • Hyperinsulinism / blood
  • Hyperinsulinism / drug therapy
  • Hyperinsulinism / veterinary
  • Insulin / blood
  • Insulin / metabolism
  • Insulin Secretion
  • Male
  • Octreotide / therapeutic use
  • Somatostatin / analogs & derivatives

References

This article includes 21 references
  1. Patel YC. Somatostatin and its receptor family.. Front Neuroendocrinol 1999 Jul;20(3):157-98.
    pubmed: 10433861doi: 10.1006/frne.1999.0183google scholar: lookup
  2. Brereton MF, Vergari E, Zhang Q, Clark A. Alpha-, Delta- and PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination?. J Histochem Cytochem 2015 Aug;63(8):575-91.
    pmc: PMC4530398pubmed: 26216135doi: 10.1369/0022155415583535google scholar: lookup
  3. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.. Proc Natl Acad Sci U S A 1992 Jan 1;89(1):251-5.
    pmc: PMC48214pubmed: 1346068doi: 10.1073/pnas.89.1.251google scholar: lookup
  4. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype.. Biochem Biophys Res Commun 1993 Sep 15;195(2):844-52.
    pubmed: 8373420doi: 10.1006/bbrc.1993.2122google scholar: lookup
  5. Hofland LJ. Somatostatin and somatostatin receptors in Cushing's disease.. Mol Cell Endocrinol 2008 May 14;286(1-2):199-205.
    pubmed: 18221833doi: 10.1016/j.mce.2007.10.015google scholar: lookup
  6. McKeage K. Pasireotide in Acromegaly: A Review.. Drugs 2015 Jun;75(9):1039-48.
    pubmed: 26017304doi: 10.1007/s40265-015-0413-ygoogle scholar: lookup
  7. Sojka JE, Weiss JS, Samuels ML, You GM. Effect of the somatostatin analogue octreotide on gastric fluid pH in ponies.. Am J Vet Res 1992 Oct;53(10):1818-21.
    pubmed: 1456527
  8. Aurich JE, Kranski S, Parvizi N, Aurich C. Somatostatin treatment affects testicular function in stallions.. Theriogenology 2003 Jun;60(1):163-74.
    pubmed: 12620589doi: 10.1016/s0093-691x(02)01361-4google scholar: lookup
  9. Tóth F, Frank N, Martin-Jiménez T, Elliott SB, Geor RJ, Boston RC. Measurement of C-peptide concentrations and responses to somatostatin, glucose infusion, and insulin resistance in horses.. Equine Vet J 2010 Mar;42(2):149-55.
    pubmed: 20156251doi: 10.2746/042516409x478497google scholar: lookup
  10. McKnight JA, McCance DR, Sheridan B, McIlrath E, Hadden DR, Kennedy L, Atkinson AB. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.. Clin Endocrinol (Oxf) 1991 Feb;34(2):119-25.
  11. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.. Gut 1994;35(3 Suppl):S1-4.
    pmc: PMC1374387pubmed: 7911441doi: 10.1136/gut.35.3_suppl.s1google scholar: lookup
  12. Wang M, Shan F, Zou Y, Sun X, Zhang ZR, Fu Y, Gong T. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide.. J Control Release 2016 May 28;230:45-56.
    pubmed: 27040814doi: 10.1016/j.jconrel.2016.03.036google scholar: lookup
  13. Davies RR, Miller M, Turner SJ, Goodship TH, Cook DB, Watson M, McGill A, Orskov H, Alberti KG, Johnston DG. Effects of somatostatin analogue SMS 201-995 in normal man.. Clin Endocrinol (Oxf) 1986 Jun;24(6):665-74.
  14. Asplin KE, Sillence MN, Pollitt CC, McGowan CM. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies.. Vet J 2007 Nov;174(3):530-5.
    pubmed: 17719811doi: 10.1016/j.tvjl.2007.07.003google scholar: lookup
  15. de Laat MA, McGowan CM, Sillence MN, Pollitt CC. Equine laminitis: induced by 48 h hyperinsulinaemia in Standardbred horses.. Equine Vet J 2010 Mar;42(2):129-35.
    pubmed: 20156248doi: 10.2746/042516409x475779google scholar: lookup
  16. Frank N, Geor RJ, Bailey SR, Durham AE, Johnson PJ. Equine metabolic syndrome.. J Vet Intern Med 2010 May-Jun;24(3):467-75.
  17. Schuver A, Frank N, Chameroy KA. Assessment of insulin and glucose dynamics by using an oral sugar test in horses. J Equine Vet Sci 2014;34:465–470.
  18. Firshman AM, Valberg SJ. Factors affecting clinical assessment of insulin sensitivity in horses.. Equine Vet J 2007 Nov;39(6):567-75.
    pubmed: 18065318doi: 10.2746/042516407x238512google scholar: lookup
  19. Slingerland LI, Voorhout G, Rijnberk A, Kooistra HS. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.. Domest Anim Endocrinol 2008 Nov;35(4):352-61.
  20. Scudder CJ, Gostelow R, Forcada Y, Schmid HA, Church D, Niessen SJ. Pasireotide for the Medical Management of Feline Hypersomatotropism.. J Vet Intern Med 2015 Jul-Aug;29(4):1074-80.
    pmc: PMC4895359pubmed: 25945588doi: 10.1111/jvim.12608google scholar: lookup
  21. Simpson KW, Stepien RL, Elwood CM, Boswood A, Vaillant CR. Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs.. J Small Anim Pract 1995 Apr;36(4):161-5.

Citations

This article has been cited 0 times.